NA Radioimmunoassay Market - Industry Trends and Forecast to 2030

Description

List of Tables

North America radioimmunoassay market is projected to register a substantial CAGR of 4.4% from 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.

Market Segmentation:

Middle East and Africa Radioimmunoassay Market, By Product Type (Radio Immunoassay Reagents and Kits and Radio Immunoassay Analyser), Application (Scientific Research and Clinical Diagnosis), End User (Hospitals, Clinical Diagnostic Laboratories, Academic and Research Institutes, Pharmaceutical and Biopharmaceutical Industry, Contract Research Organizations, and Other), Distribution Channel (Direct Tender, Online Sales, Third Party Distribution, and Others), Country (U.S., Canada, and Mexico) Industry Trends and Forecast to 2030.

Some of the major factors contributing to the growth of North America radioimmunoassay market are:

Increase in the demand for error-free and accurate results of high throughput and automated procedures

Rise in the technological advancements

Strategic initiatives by market players

Increasing significance of research and development in medical science

Market Players:

The key market players in North America radioimmunoassay market are listed below:

PerkinElmer Inc.

MP BIOMEDICALS

Tecan Trading AG

Merck KGaA

Immuno-Biological Laboratories Co,Ltd.

EUROIMMUN Medizinische Labordiagnostika AG

KAMIYA BIOMEDICAL COMPANY

Beckman Coulter, Inc.

MyBioSource.com.

Berthold Technologies GmbH & Co.KG

Hidex Oy.

Abcam plc

1 INTRODUCTION 65

1.1 OBJECTIVES OF THE STUDY 65
1.2 MARKET DEFINITION 65
1.3 OVERVIEW OF NORTH AMERICA RADIOIMMUNOASSAY MARKET 65
1.4 LIMITATIONS 67
1.5 MARKETS COVERED 67

2 MARKET SEGMENTATION 71

2.1 MARKETS COVERED 71
2.2 GEOGRAPHICAL SCOPE 72
2.3 YEARS CONSIDERED FOR THE STUDY 73
2.4 CURRENCY AND PRICING 73
2.5 DBMR TRIPOD DATA VALIDATION MODEL 74
2.6 MULTIVARIATE MODELLING 77
2.7 PRODUCT TYPE LIFELINE CURVE 77
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 78
2.9 DBMR MARKET POSITION GRID 79
2.10 MARKET TESTING TYPE COVERAGE GRID 81
2.11 VENDOR SHARE ANALYSIS 82
2.12 SECONDARY SOURCES 83
2.13 ASSUMPTIONS 83

3 EXECUTIVE SUMMARY 84

4 PREMIUM INSIGHTS 87

4.1 PESTEL ANALYSIS 88
4.2 PORTYER'S FIVE FORCES 89
4.3 GROWTH STRATEGIES ADOPTED BY KEY MARKET PLAYERS 90

5 INDUSTRY INSIGHTS: 91

6 REGULATORY GUIDELINES FOR RADIOIMMUNOASSAY 92

6.1 U.S REGULATORY GUIDELINES FOR RADIOIMMUNOASSAY 92
6.2 EUROPE REGULATORY GUIDELINE FOR RADIOIMMUNOASSAY 92
6.3 INDIA REGULATORY GUIDELINE FOR RADIOIMMUNOASSAY 93
6.4 CHINA REGULATORY GUIDELINE FOR RADIOIMMUNOASSAY 94

7 MARKET OVERVIEW 95

7.1 DRIVERS 97
- 7.1.1 INCREASE IN THE DEMAND FOR ERROR-FREE AND ACCURATE RESULTS OF HIGH THROUGHPUT AND AUTOMATED PROCEDURES 97
- 7.1.2 RISE IN THE PREVALENCE AND INCIDENCE OF INFECTIOUS DISEASES 97
- 7.1.3 RISE IN THE TECHNOLOGICAL ADVANCEMENTS 98
7.2 RESTRAINTS 98
- 7.2.1 HIGH COST OF INSTALLATION AND MAINTENANCE OF RADIOIMMUNOASSAY KITS 98
- 7.2.2 SHORT SHELF-LIFE OF RADIOLABELED COMPOUNDS 99
- 7.2.3 ADVERSE EFFECTS OF HAZARDOUS RADIOACTIVE ELEMENTS 99
7.3 OPPORTUNITIES 100
- 7.3.1 INCREASING SIGNIFICANCE OF RESEARCH AND DEVELOPMENT IN MEDICAL SCIENCE 100
- 7.3.2 RISE IN GOVERNMENT FUNDING AND OVERALL HEALTHCARE EXPENDITURE 100
- 7.3.3 STRATEGIC INITIATIVES BY MARKET PLAYERS 101
7.4 CHALLENGES 103
- 7.4.1 LACK OF SKILLED PROFESSIONALS 103
- 7.4.2 NEW INNOVATIONS IN VARIOUS OTHER IMMUNOASSAY PROCEDURES 103

8 NORTH AMERICA RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE 104

8.1 OVERVIEW 105
8.2 RADIOIMMUNOASSAY REAGENTS AND KITS 108
- 8.2.1 KITS 109
- 8.2.2 BUFFER 109
  - 8.2.2.1 SOLUTION 109
  - 8.2.2.2 POWDER 109
- 8.2.3 STANDARD CONCENTRATES 110
- 8.2.4 PRECIPITATING REAGENTS 110
- 8.2.5 RADIOISOTOPES 110
  - 8.2.5.1 BETA EMITTERS 110
    - 8.2.5.1.1 TRITIUM 110
    - 8.2.5.1.2 CARBON-14 111
  - 8.2.5.2 GAMMA EMITTERS 111
    - 8.2.5.2.1 IODINE-125 111
    - 8.2.5.2.2 CHROMIUM-51 111
    - 8.2.5.2.3 COBALT-57 111
- 8.2.6 ANTIBODY/ANTISERUM 112
  - 8.2.6.1 POLYCLONAL 112
  - 8.2.6.2 MONOCLONAL 112
- 8.2.7 OTHERS 112
8.3 RADIOIMMUNOASSAY ANALYZER 113

9 NORTH AMERICA RADIOIMMUNOASSAY MARKET: BY APPLICATION 114

9.1 OVERVIEW 115
9.2 SCIENTIFIC RESEARCH 118
- 9.2.1 RADIOIMMUNOASSAY REAGENTS AND KITS 119
- 9.2.2 RADIOIMMUNOASSAY ANALYZER 119
9.3 CLINICAL DIAGNOSIS 119
- 9.3.1 INFECTIOUS DISEASE TESTING 120
  - 9.3.1.1 RADIOIMMUNOASSAY REAGENTS AND KITS 120
  - 9.3.1.2 RADIOIMMUNOASSAY ANALYZER 120
- 9.3.2 ALLERGY TESTING 121
  - 9.3.2.1 RADIOIMMUNOASSAY REAGENTS AND KITS 121
  - 9.3.2.2 RADIOIMMUNOASSAY ANALYZER 121
- 9.3.3 ONCOLOGY TESTING 121
  - 9.3.3.1 RADIOIMMUNOASSAY REAGENTS AND KITS 121
  - 9.3.3.2 RADIOIMMUNOASSAY ANALYZER 122
- 9.3.4 ENDOCRINE TESTING 122
  - 9.3.4.1 RADIOIMMUNOASSAY REAGENTS AND KITS 122
  - 9.3.4.2 RADIOIMMUNOASSAY ANALYZER 122
- 9.3.5 TOXICOLOGY TESTING 123
  - 9.3.5.1 RADIOIMMUNOASSAY REAGENTS AND KITS 123
  - 9.3.5.2 RADIOIMMUNOASSAY ANALYZER 123
- 9.3.6 AUTOIMMUNE DISEASE TESTING 123
  - 9.3.6.1 RADIOIMMUNOASSAY REAGENTS AND KITS 124
  - 9.3.6.2 RADIOIMMUNOASSAY ANALYZER 124
- 9.3.7 OTHER DISEASE TESTING 124

10 NORTH AMERICA RADIOIMMUNOASSAY MARKET, BY END USER 125

10.1 OVERVIEW 126
10.2 HOSPITALS 129
10.3 CLINICAL DIAGNOSTIC LABORATORIES 129
10.4 ACADEMIC AND RESEARCH INSTITUTES 130
10.5 PHARMACEUTICAL AND BIOPHARMACEUTICAL INDUSTRY 131
10.6 CONTRACT RESEARCH ORGANISATIONS 131
10.7 OTHERS 132

11 NORTH AMERICA RADIOIMMUNOASSAY MARKET, BY DISTRIBUTION CHANNEL 133

11.1 OVERVIEW 134
11.2 DIRECT TENDER 137
11.3 ONLINE SALES 138
11.4 THIRD PARTY DISTRIBUTIONS 139
11.5 OTHERS 140

12 NORTH AMERICA RADIOIMMUNOASSAY MARKET, BY REGION 141

12.1 NORTH AMERICA 142
- 12.1.1 U.S. 154
- 12.1.2 CANADA 161
- 12.1.3 MEXICO 168

13 NORTH AMERICA RADIOIMMUNOASSAY MARKET: COMPANY LANDSCAPE 175

13.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 175

14 SWOT ANALYSIS 176

15 COMPANY PROFILE 177

15.1 PERKINELMER INC. 177
- 15.1.1 COMPANY SNAPSHOT 177
- 15.1.2 REVENUE ANALYSIS 177
- 15.1.3 COMPANY SHARE ANALYSIS 178
- 15.1.4 PRODUCT PORTFOLIO 178
- 15.1.4 RECENT DEVELOPMENT 179
15.2 MERCK KGAA 180
- 15.2.1 COMPANY SNAPSHOT 180
- 15.2.2 REVENUE ANALYSIS 180
- 15.2.3 COMPANY SHARE ANALYSIS 181
- 15.2.4 PRODUCT PORTFOLIO 181
- 15.2.5 RECENT DEVELOPMENTS 181
15.3 BECKMAN COULTER, INC. 183
- 15.3.1 COMPANY SNAPSHOT 183
- 15.3.2 COMPANY SHARE ANALYSIS 183
- 15.3.3 PRODUCT PORTFOLIO 183
- 15.3.4 RECENT DEVELOPMENT 184
15.4 ABCAM PLC 185
- 15.4.1 COMPANY SNAPSHOT 185
- 15.4.2 REVENUE ANALYSIS 185
- 15.4.3 COMPANY SHARE ANALYSIS 186
- 15.4.4 PRODUCT PORTFOLIO 186
- 15.4.5 RECENT DEVELOPMENT 186
15.5 TECAN TRADING AG 187
- 15.5.1 COMPANY SNAPSHOT 187
- 15.5.2 REVENUE ANALYSIS 187
- 15.5.3 COMPANY SHARE ANALYSIS 188
- 15.5.4 PRODUCT PORTFOLIO 188
- 15.5.5 RECENT DEVELOPMENT 189
15.6 BERTHOLD TECHNOLOGIES GMBH & CO.KG 190
- 15.6.1 COMPANY SNAPSHOT 190
- 15.6.2 PRODUCT PORTFOLIO 190
- 15.6.3 RECENT DEVELOPMENTS 190
15.7 DEMEDITEC DIAGNOSTICS GMBH 191
- 15.7.1 COMPANY SNAPSHOT 191
- 15.7.2 PRODUCT PORTFOLIO 191
- 15.7.3 RECENT DEVELOPMENTS 192
15.8 DIASOURCE 193
- 15.8.1 COMPANY SNAPSHOT 193
- 15.8.2 PRODUCT PORTFOLIO 193
- 15.8.3 RECENT DEVELOPMENT 193
15.9 EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG 194
- 15.9.1 COMPANY SNAPSHOT 194
- 15.9.2 PRODUCT PORTFOLIO 194
- 15.9.3 RECENT DEVELOPMENTS 194
15.10 HIDEX OY 196
- 15.10.1 COMPANY SNAPSHOT 196
- 15.10.2 PRODUCT PORTFOLIO 196
- 15.10.3 RECENT DEVELOPMENTS 196
15.11 IMMUNO-BIOLOGICAL LABORATORIES CO,LTD. 197
- 15.11.1 COMPANY SNAPSHOT 197
- 15.11.2 PRODUCT PORTFOLIO 197
- 15.11.3 RECENT DEVELOPMENT 199
15.12 INSTITUTE OF ISOTOPES 200
- 15.12.1 COMPANY SNAPSHOT 200
- 15.12.2 PRODUCT PORTFOLIO 200
- 15.12.3 RECENT DEVELOPMENTS 201
15.13 KAMIYA BIOMEDICAL COMPANY 202
- 15.13.1 COMPANY SNAPSHOT 202
- 15.13.2 PRODUCT PORTFOLIO 202
- 15.13.3 RECENT DEVELOPMENTS 202
15.14 MP BIOMEDICALS 203
- 15.14.1 COMPANY SNAPSHOT 203
- 15.14.2 PRODUCT PORTFOLIO 203
- 15.14.3 RECENT DEVELOPMENTS 204
15.15 MYBIOSOURCE.COM. 205
- 15.15.1 COMPANY SNAPSHOT 205
- 15.15.2 PRODUCT PORTFOLIO 205
- 15.15.3 RECENT DEVELOPMENT 205

16 QUESTIONNAIRE 206

17 RELATED REPORTS 209

LIST OF TABLES

TABLE 1 LIST OF IN-VITRO DIAGNOSTIC MEDICAL DEVICES (IVD ANALYZERS) UNDER PROVISIONS OF SUB-RULE (2) RULE 4 OF THE MEDICAL DEVICES RULES, 2017 48
TABLE 2 COST OF RIA KITS IS MENTIONED BELOW 53
TABLE 3 DECOMPOSITION RATES OF A FEW RADIOLABELED ISOTOPES ARE MENTIONED IN THE BELOW TABLE 54
TABLE 4 NORTH AMERICA RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 62
TABLE 5 NORTH AMERICA RADIOIMMUNOASSAY REAGENTS AND KITS IN RADIOIMMUNOASSAY MARKET, BY REGION, 2021-2030 (USD MILLION) 63
TABLE 6 NORTH AMERICA RADIOIMMUNOASSAY REAGENTS AND KITS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 64
TABLE 7 NORTH AMERICA BUFFER IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 64
TABLE 8 NORTH AMERICA RADIOISOTOPES IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 65
TABLE 9 NORTH AMERICA BETA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 65
TABLE 10 NORTH AMERICA GAMMA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 66
TABLE 11 NORTH AMERICA ANTIBODY/ANTISERUM IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 67
TABLE 12 NORTH AMERICA RADIOIMMUNOASSAY ANALYZER IN RADIOIMMUNOASSAY MARKET, BY REGION, 2021-2030 (USD MILLION) 68
TABLE 13 NORTH AMERICA RADIOIMMUNOASSAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 72
TABLE 14 NORTH AMERICA SCIENTIFIC RESEARCH IN RADIOIMMUNOASSAY MARKET, BY REGION, 2021-2030 (USD MILLION) 73
TABLE 15 NORTH AMERICA SCIENTIFIC RESEARCH IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 73
TABLE 16 NORTH AMERICA CLINICAL DIAGNOSIS IN RADIOIMMUNOASSAY MARKET, BY REGION, 2021-2030 (USD MILLION) 74
TABLE 17 NORTH AMERICA CLINICAL DIAGNOSIS IN RADIOIMMUNOASSAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 75
TABLE 18 NORTH AMERICA INFECTIOUS DISEASE TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 75
TABLE 19 NORTH AMERICA ALLERGY TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 76
TABLE 20 NORTH AMERICA ONCOLOGY TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 76
TABLE 21 NORTH AMERICA ENDOCRINE TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 77
TABLE 22 NORTH AMERICA TOXICOLOGY TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE 2021-2030 (USD MILLION) 78
TABLE 23 NORTH AMERICA AUTOIMMUNE DISEASE TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 78
TABLE 24 NORTH AMERICA RADIOIMMUNOASSAY MARKET, BY END USER, 2021-2030 (USD MILLION) 83
TABLE 25 NORTH AMERICA HOSPITALS IN RADIOIMMUNOASSAY MARKET, BY REGION, 2021-2030 (USD MILLION) 84
TABLE 26 NORTH AMERICA CLINICAL DIAGNOSTIC LABORATORIES IN RADIOIMMUNOASSAY MARKET, BY REGION, 2021-2030 (USD MILLION) 85
TABLE 27 NORTH AMERICA ACADEMIC AND RESEARCH INSTITUTES IN RADIOIMMUNOASSAY MARKET, BY REGION, 2021-2030 (USD MILLION) 85
TABLE 28 NORTH AMERICA PHARMACEUTICAL AND BIOPHARMACEUTICAL INDUSTRY IN RADIOIMMUNOASSAY MARKET, BY REGION, 2021-2030 (USD MILLION) 86
TABLE 29 NORTH AMERICA CONTRACT RESEARCH ORGANISATIONS IN RADIOIMMUNOASSAY MARKET, BY REGION, 2021-2030 (USD MILLION) 87
TABLE 30 NORTH AMERICA OTHERS IN RADIOIMMUNOASSAY MARKET, BY REGION, 2021-2030 (USD MILLION) 87
TABLE 31 NORTH AMERICA RADIOIMMUNOASSAY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 91
TABLE 32 NORTH AMERICA DIRECT TENDER IN RADIOIMMUNOASSAY MARKET, BY REGION, 2021-2030 (USD MILLION) 92
TABLE 33 NORTH AMERICA ONLINE SALES IN RADIOIMMUNOASSAY MARKET, BY REGION, 2021-2030 (USD MILLION) 93
TABLE 34 NORTH AMERICA THIRD PARTY DISTRIBUTION IN RADIOIMMUNOASSAY MARKET, BY REGION, 2021-2030 (USD MILLION) 94
TABLE 35 NORTH AMERICA OTHERS IN RADIOIMMUNOASSAY MARKET, BY REGION, 2021-2030 (USD MILLION) 95
TABLE 36 NORTH AMERICA RADIOIMMUNOASSAY MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 101
TABLE 37 NORTH AMERICA RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 101
TABLE 38 NORTH AMERICA RADIOIMMUNOASSAY REAGENTS AND KITS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 101
TABLE 39 NORTH AMERICA RADIOIMMUNOASSAY REAGENTS AND KITS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME) 102
TABLE 40 NORTH AMERICA RADIOIMMUNOASSAY REAGENTS AND KITS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD) 102
TABLE 41 NORTH AMERICA BUFFER IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 102
TABLE 42 NORTH AMERICA BUFFER IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME) 102
TABLE 43 NORTH AMERICA BUFFER IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD) 102
TABLE 44 NORTH AMERICA RADIOISOTOPES IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 103
TABLE 45 NORTH AMERICA BETA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 103
TABLE 46 NORTH AMERICA BETA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME) 103
TABLE 47 NORTH AMERICA BETA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD) 103
TABLE 48 NORTH AMERICA GAMMA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 103
TABLE 49 NORTH AMERICA GAMMA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME) 104
TABLE 50 NORTH AMERICA GAMMA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD) 104
TABLE 51 NORTH AMERICA ANTIBODY/ANTISERUM IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030(USD MILLION) 104
TABLE 52 NORTH AMERICA ANTIBODY/ANTISERUM IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030(VOLUME) 104
TABLE 53 NORTH AMERICA ANTIBODY/ANTISERUM IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030(ASP IN USD) 104
TABLE 54 NORTH AMERICA RADIO IMMUNO ANALYZERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME) 105
TABLE 55 NORTH AMERICA RADIO IMMUNO ANALYZERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD) 105
TABLE 56 NORTH AMERICA RADIOIMMUNOASSAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 105
TABLE 57 NORTH AMERICA SCIENTIFIC RESEARCH IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 105
TABLE 58 NORTH AMERICA CLINICAL DIAGNOSIS IN RADIOIMMUNOASSAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 106
TABLE 59 NORTH AMERICA INFECTIOUS DISEASE TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 106
TABLE 60 NORTH AMERICA ALLERGY TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 106
TABLE 61 NORTH AMERICA ONCOLOGY TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 107
TABLE 62 NORTH AMERICA ENDOCRINE TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 107
TABLE 63 NORTH AMERICA TOXICOLOGY TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE 2021-2030 (USD MILLION) 107
TABLE 64 NORTH AMERICA AUTOIMMUNE DISEASE TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 107
TABLE 65 NORTH AMERICA RADIOIMMUNOASSAY MARKET, BY END USER, 2021-2030 (USD MILLION) 108
TABLE 66 NORTH AMERICA RADIOIMMUNOASSAY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 108
TABLE 67 U.S. RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 109
TABLE 68 U.S. RADIOIMMUNOASSAY REAGENTS AND KITS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 109
TABLE 69 U.S. RADIOIMMUNOASSAY REAGENTS AND KITS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME) 109
TABLE 70 U.S. RADIOIMMUNOASSAY REAGENTS AND KITS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD) 110
TABLE 71 U.S. BUFFER IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 110
TABLE 72 U.S. BUFFER IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME) 110
TABLE 73 U.S. BUFFER IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD) 110
TABLE 74 U.S. RADIOISOTOPES IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 110
TABLE 75 U.S. BETA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 111
TABLE 76 U.S. BETA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME) 111
TABLE 77 U.S. BETA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD) 111
TABLE 78 U.S. GAMMA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 111
TABLE 79 U.S. GAMMA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME) 111
TABLE 80 U.S. GAMMA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD) 112
TABLE 81 U.S. ANTIBODY/ANTISERUM IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030(USD MILLION) 112
TABLE 82 U.S. ANTIBODY/ANTISERUM IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030(VOLUME) 112
TABLE 83 U.S. ANTIBODY/ANTISERUM IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030(ASP IN USD) 112
TABLE 84 U.S. RADIO IMMUNO ANALYZERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME) 112
TABLE 85 U.S. RADIO IMMUNO ANALYZERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD) 113
TABLE 86 U.S. RADIOIMMUNOASSAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 113
TABLE 87 U.S. SCIENTIFIC RESEARCH IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 113
TABLE 88 U.S. CLINICAL DIAGNOSIS IN RADIOIMMUNOASSAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 113
TABLE 89 U.S. INFECTIOUS DISEASE TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 114
TABLE 90 U.S. ALLERGY TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 114
TABLE 91 U.S. ONCOLOGY TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 114
TABLE 92 U.S. ENDOCRINE TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 114
TABLE 93 U.S. TOXICOLOGY TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE 2021-2030 (USD MILLION) 115
TABLE 94 U.S. AUTOIMMUNE DISEASE TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 115
TABLE 95 U.S. RADIOIMMUNOASSAY MARKET, BY END USER, 2021-2030 (USD MILLION) 115
TABLE 96 U.S. RADIOIMMUNOASSAY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 115
TABLE 97 CANADA RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 116
TABLE 98 CANADA RADIOIMMUNOASSAY REAGENTS AND KITS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 116
TABLE 99 CANADA RADIOIMMUNOASSAY REAGENTS AND KITS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME) 116
TABLE 100 CANADA RADIOIMMUNOASSAY REAGENTS AND KITS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD) 117
TABLE 101 CANADA BUFFER IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 117
TABLE 102 CANADA BUFFER IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME) 117
TABLE 103 CANADA BUFFER IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD) 117
TABLE 104 CANADA RADIOISOTOPES IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 117
TABLE 105 CANADA BETA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 118
TABLE 106 CANADA BETA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME) 118
TABLE 107 CANADA BETA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD) 118
TABLE 108 CANADA GAMMA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 118
TABLE 109 CANADA GAMMA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME) 118
TABLE 110 CANADA GAMMA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD) 119
TABLE 111 CANADA ANTIBODY/ANTISERUM IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030(USD MILLION) 119
TABLE 112 CANADA ANTIBODY/ANTISERUM IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030(VOLUME) 119
TABLE 113 CANADA ANTIBODY/ANTISERUM IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030(ASP IN USD) 119
TABLE 114 CANADA RADIO IMMUNO ANALYZERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME) 119
TABLE 115 CANADA RADIO IMMUNO ANALYZERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD) 120
TABLE 116 CANADA RADIOIMMUNOASSAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 120
TABLE 117 CANADA SCIENTIFIC RESEARCH IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 120
TABLE 118 CANADA CLINICAL DIAGNOSIS IN RADIOIMMUNOASSAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 120
TABLE 119 CANADA INFECTIOUS DISEASE TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 121
TABLE 120 CANADA ALLERGY TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 121
TABLE 121 CANADA ONCOLOGY TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 121
TABLE 122 CANADA ENDOCRINE TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 121
TABLE 123 CANADA TOXICOLOGY TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE 2021-2030 (USD MILLION) 122
TABLE 124 CANADA AUTOIMMUNE DISEASE TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 122
TABLE 125 CANADA RADIOIMMUNOASSAY MARKET, BY END USER, 2021-2030 (USD MILLION) 122
TABLE 126 CANADA RADIOIMMUNOASSAY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 122
TABLE 127 MEXICO RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 123
TABLE 128 MEXICO RADIOIMMUNOASSAY REAGENTS AND KITS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 123
TABLE 129 MEXICO RADIOIMMUNOASSAY REAGENTS AND KITS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME) 123
TABLE 130 MEXICO RADIOIMMUNOASSAY REAGENTS AND KITS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD) 124
TABLE 131 MEXICO BUFFER IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 124
TABLE 132 MEXICO BUFFER IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME) 124
TABLE 133 MEXICO BUFFER IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD) 124
TABLE 134 MEXICO RADIOISOTOPES IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 124
TABLE 135 MEXICO BETA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 125
TABLE 136 MEXICO

TABLE 136 MEXICO BETA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME) 125
TABLE 137 MEXICO BETA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD) 125
TABLE 138 MEXICO GAMMA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 125
TABLE 139 MEXICO GAMMA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME) 125
TABLE 140 MEXICO GAMMA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD) 126
TABLE 141 MEXICO ANTIBODY/ANTISERUM IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030(USD MILLION) 126
TABLE 142 MEXICO ANTIBODY/ANTISERUM IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030(VOLUME) 126
TABLE 143 MEXICO ANTIBODY/ANTISERUM IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030(ASP IN USD) 126
TABLE 144 MEXICO RADIO IMMUNO ANALYZERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME) 126
TABLE 145 MEXICO RADIO IMMUNO ANALYZERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD) 127
TABLE 146 MEXICO RADIOIMMUNOASSAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 127
TABLE 147 MEXICO SCIENTIFIC RESEARCH IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 127
TABLE 148 MEXICO CLINICAL DIAGNOSIS IN RADIOIMMUNOASSAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 127
TABLE 149 MEXICO INFECTIOUS DISEASE TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 128
TABLE 150 MEXICO ALLERGY TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 128
TABLE 151 MEXICO ONCOLOGY TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 128
TABLE 152 MEXICO ENDOCRINE TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 128
TABLE 153 MEXICO TOXICOLOGY TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE 2021-2030 (USD MILLION) 129
TABLE 154 MEXICO AUTOIMMUNE DISEASE TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 129
TABLE 155 MEXICO RADIOIMMUNOASSAY MARKET, BY END USER, 2021-2030 (USD MILLION) 129
TABLE 156 MEXICO RADIOIMMUNOASSAY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 129

LIST OF FIGURES

FIGURE 1 NORTH AMERICA RADIOIMMUNOASSAY MARKET: SEGMENTATION 25
FIGURE 2 NORTH AMERICA RADIOIMMUNOASSAY MARKET: DATA TRIANGULATION 28
FIGURE 3 NORTH AMERICA RADIOIMMUNOASSAY MARKET: DROC ANALYSIS 29
FIGURE 4 NORTH AMERICA RADIOIMMUNOASSAY MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS 30
FIGURE 5 NORTH AMERICA RADIOIMMUNOASSAY: COMPANY RESEARCH ANALYSIS 30
FIGURE 6 NORTH AMERICA RADIOIMMUNOASSAY MARKET: INTERVIEW DEMOGRAPHICS 32
FIGURE 7 NORTH AMERICA RADIOIMMUNOASSAY MARKET: DBMR MARKET POSITION GRID 33
FIGURE 8 NORTH AMERICA RADIOIMMUNOASSAY MARKET: MARKET TESTING TYPE COVERAGE GRID 35
FIGURE 9 NORTH AMERICA RADIOIMMUNOASSAY MARKET: VENDOR SHARE ANALYSIS 36
FIGURE 10 NORTH AMERICA RADIOIMMUNOASSAY MARKET: SEGMENTATION 40
FIGURE 11 RISING PREVALENCE AND INCIDENCE OF INFECTIOUS DISEASES ARE EXPECTED TO DRIVE THE NORTH AMERICA RADIOIMMUNOASSAY MARKET IN THE FORECAST PERIOD 41
FIGURE 12 PRODUCT TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA RADIOIMMUNOASSAY MARKET IN 2023 & 2030 41
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA RADIOIMMUNOASSAY MARKET 50
FIGURE 14 NORTH AMERICA RADIOIMMUNOASSAY MARKET: BY PRODUCT TYPE, 2022 59
FIGURE 15 NORTH AMERICA RADIOIMMUNOASSAY MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION) 60
FIGURE 16 NORTH AMERICA RADIOIMMUNOASSAY MARKET: BY PRODUCT TYPE, CAGR (2023-2030) 60
FIGURE 17 NORTH AMERICA RADIOIMMUNOASSAY MARKET: PRODUCT TYPE, LIFELINE CURVE 61
FIGURE 18 NORTH AMERICA RADIOIMMUNOASSAY MARKET: BY APPLICATION, 2022 69
FIGURE 19 NORTH AMERICA RADIOIMMUNOASSAY MARKET: BY APPLICATION, 2023-2030 (USD MILLION) 70
FIGURE 20 NORTH AMERICA RADIOIMMUNOASSAY MARKET: BY APPLICATION, CAGR (2023-2030) 70
FIGURE 21 NORTH AMERICA RADIOIMMUNOASSAY MARKET: BY APPLICATION, LIFELINE CURVE 71
FIGURE 22 NORTH AMERICA RADIOIMMUNOASSAY MARKET: BY END USER, 2022 80
FIGURE 23 NORTH AMERICA RADIOIMMUNOASSAY MARKET: BY END USER, 2023-2030 (USD MILLION) 81
FIGURE 24 NORTH AMERICA RADIOIMMUNOASSAY MARKET: BY END USER, CAGR (2023-2030) 81
FIGURE 25 NORTH AMERICA RADIOIMMUNOASSAY MARKET : BY END USER, LIFELINE CURVE 82
FIGURE 26 NORTH AMERICA RADIOIMMUNOASSAY MARKET: BY DISTRIBUTION CHANNEL, 2022 88
FIGURE 27 NORTH AMERICA RADIOIMMUNOASSAY MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 89
FIGURE 28 NORTH AMERICA RADIOIMMUNOASSAY MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 89
FIGURE 29 NORTH AMERICA RADIOIMMUNOASSAY MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 90
FIGURE 30 NORTH AMERICA RADIOIMMUNOASSAY MARKET: SNAPSHOT (2022) 97
FIGURE 31 NORTH AMERICA RADIOIMMUNOASSAY MARKET: BY COUNTRY (2022) 98
FIGURE 32 NORTH AMERICA RADIOIMMUNOASSAY MARKET: BY COUNTRY (2023 & 2030) 98
FIGURE 33 NORTH AMERICA RADIOIMMUNOASSAY MARKET: BY COUNTRY (2022 & 2030) 99
FIGURE 34 NORTH AMERICA RADIOIMMUNOASSAY MARKET: PRODUCT TYPE (2023-2030) 99
FIGURE 35 NORTH AMERICA RADIOIMMUNOASSAY MARKET: COMPANY SHARE 2022 (%) 129